This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol 27, 781–783 (2009). https://doi.org/10.1038/nbt0909-781
Issue Date:
DOI: https://doi.org/10.1038/nbt0909-781
This article is cited by
-
BMS bets on targeting IL-8 to enhance cancer immunotherapies
Nature Biotechnology (2016)
-
Industry pursues co-stimulatory receptor immunomodulators to treat cancer
Nature Biotechnology (2013)
-
Cautious optimism surrounds early clinical data for PD-1 blocker
Nature Biotechnology (2012)
-
p38 kinase inhibitor approved for idiopathic pulmonary fibrosis
Nature Biotechnology (2011)
-
Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall
Nature Biotechnology (2010)